“Let us go abroad beyond domestic market”… Pharmaceutical industry to grow in global market
Kim Ji Seob | cloud50@ | 2017-12-26 11:02:51
The pharmaceutical industry has been carrying out a series of greetings focused on overseas market entry next year. We are moving away from the domestic market and entering overseas markets. We are recruiting new talent for global strategy.
According to the pharmaceutical industry on December 25, Hugel has recently held a board meeting and appointed former chairman Son Ji-hoon as the co-representative of the country.
After completing his MBA at Boston University in USA, he worked as head of the US BMS headquarters and as head of the global business division of Dong-A Pharm. He was the CEO of Baxter Korea, a global company. Hugel`s strategy is to accelerate the advancement of botulinum toxin, Botulex, etc., in the future through the recruitment of a co-representative.
Meanwhile, Ildong Pharma appointed Dr. Choi Sung-koo to the head of the central research department on the 1st. Choi Seong-koo, a graduate of SNU`s Department of Medicine, has been involved in a number of global drug development and clinical trials through the Department of Medicine and Marketing at Jansen Korea. Choi will lead Ildong Pharmaceutical `s global new drug development projects based on his many years of experience in global clinical trials.
As a result, Ildong Pharm`s global drug development projects are expected to accelerate, including IDX-1197, a novel anti-cancer drug targeting the poly ADP Ribos Polymer Lace (PARP).
Boryung Pharmaceutical recently acquired Lee Sun-wook, managing director of Global Business Division last month. Lee is a graduate of Seoul National University and Chung-Ang University College of Medicine. He joined Green Cross in 1997 and served as the Head of the Pharmaceutical Information & Business Development Division and the Global Marketing Division.
Vyhomed recruited overseas experts last month to build a global team to develop the gene therapy product `VM202` as a global new drug.
Dr. William Schmidt, Vice President of Clinical Development at Vyhomed, on the other hand, is a clinical and regulatory authority with more than 40 years experience in developing pain medicines.
"In order to advance into overseas markets, domestic companies are recruiting experts who have gained experience in multinational pharmaceutical companies." The government also supports networking and ecosystem development to attract talented foreign talent, We should create a corporate culture that will enable foreign talent to exert their strengths. "
By Kim Ji Seob cloud50@
[ copyright ⓒ The Digitaltimes ]
According to the pharmaceutical industry on December 25, Hugel has recently held a board meeting and appointed former chairman Son Ji-hoon as the co-representative of the country.
After completing his MBA at Boston University in USA, he worked as head of the US BMS headquarters and as head of the global business division of Dong-A Pharm. He was the CEO of Baxter Korea, a global company. Hugel`s strategy is to accelerate the advancement of botulinum toxin, Botulex, etc., in the future through the recruitment of a co-representative.
Meanwhile, Ildong Pharma appointed Dr. Choi Sung-koo to the head of the central research department on the 1st. Choi Seong-koo, a graduate of SNU`s Department of Medicine, has been involved in a number of global drug development and clinical trials through the Department of Medicine and Marketing at Jansen Korea. Choi will lead Ildong Pharmaceutical `s global new drug development projects based on his many years of experience in global clinical trials.
As a result, Ildong Pharm`s global drug development projects are expected to accelerate, including IDX-1197, a novel anti-cancer drug targeting the poly ADP Ribos Polymer Lace (PARP).
Boryung Pharmaceutical recently acquired Lee Sun-wook, managing director of Global Business Division last month. Lee is a graduate of Seoul National University and Chung-Ang University College of Medicine. He joined Green Cross in 1997 and served as the Head of the Pharmaceutical Information & Business Development Division and the Global Marketing Division.
Vyhomed recruited overseas experts last month to build a global team to develop the gene therapy product `VM202` as a global new drug.
Dr. William Schmidt, Vice President of Clinical Development at Vyhomed, on the other hand, is a clinical and regulatory authority with more than 40 years experience in developing pain medicines.
"In order to advance into overseas markets, domestic companies are recruiting experts who have gained experience in multinational pharmaceutical companies." The government also supports networking and ecosystem development to attract talented foreign talent, We should create a corporate culture that will enable foreign talent to exert their strengths. "
By Kim Ji Seob cloud50@